Provided are certain CDK2/4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer. ##STR00001##

The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer. ##STR00001##

Compounds as immune system modulators bearing a pteridine core are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing autoimmunity disease using the same are described.

Compounds as immune system modulators bearing a pteridine core are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing autoimmunity disease using the same are described.

A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: ##STR00001##
(wherein, n.sup.1A represents 0 or 1; n.sup.2A and n.sup.3A may be the same or different, and each represents 1 or 2; R.sup.0A represents optionally substituted aryl or the like; R.sup.2A represents a hydrogen atom or the like; R.sup.3A represents an optionally substituted aromatic heterocyclic group or the like; X.sup.1A, X.sup.2A, X.sup.3A and X.sup.4A each represent CH or the like; Y.sup.1A represents CH.sub.2 or the like; Y.sup.2A represents N or the like; and L.sup.A represents CH.sub.2 or the like).

A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: ##STR00001##
(wherein, n.sup.1A represents 0 or 1; n.sup.2A and n.sup.3A may be the same or different, and each represents 1 or 2; R.sup.0A represents optionally substituted aryl or the like; R.sup.2A represents a hydrogen atom or the like; R.sup.3A represents an optionally substituted aromatic heterocyclic group or the like; X.sup.1A, X.sup.2A, X.sup.3A and X.sup.4A each represent CH or the like; Y.sup.1A represents CH.sub.2 or the like; Y.sup.2A represents N or the like; and L.sup.A represents CH.sub.2 or the like).

Disclosed are modified T-cells so that the modified T-cells are capable of penetrating the fugetactic wall generated by tumors, including solid mass tumors, as well as imparting tumor specific targeting for these modified T-cells.

The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR. ##STR00001##

The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR. ##STR00001##